Nuclear Medicine Department

The Nuclear Medicine Department of Tianjin First Central Hospital was founded in 1959. It is one of the first units in the country to establish a nuclear medicine department. It is also the most comprehensive nuclear medicine department in Tianjin. The current department director Shen Jie. The department is divided into four working modules: thyroid nuclear medicine clinic and radionuclide therapy, nuclear medicine molecular imaging (SPECT/PET-CT), nuclear medicine in vitro analysis laboratory, and radioactive drug R&D and preparation. Routinely carry out various thyroid disease treatment, tumor radionuclide therapy, various nuclear medicine imaging, hematuria specimen detection, particle implantation radiotherapy and other aspects of work. The department has an annual outpatient volume of more than 30,000, an average of more than 2,000 PET/CT examinations, an average of more than 6,000 SPECT/CT examinations annually, and an average of more than 3,300 radionuclide treatments. The department has large-scale advanced medical equipment such as the internationally advanced German Siemens PET/CT machine and dual-probe SPECT/CT machine, the German Roche Cobase 411 electrochemiluminescence instrument, and the Korean radioimmunoassay instrument. The department is responsible for the clinical teaching of nuclear medicine for graduate students and undergraduates at Nankai University, Tianjin Medical University and Tianjin Higher Medical College.It is a doctoral training unit of Tianjin Medical University, a master's training unit of Nankai University, and an affiliated unit for the leader of the Tianjin Post-Graduation Quality Control Expert Group in Nuclear Medicine. Currently, the department is responsible for 4 clinical trials, including a multi-center, randomized, double-blind, controlled phase III clinical trial comparing the effectiveness and safety of H-CHOP and R-CHOP in patients with previously treated diffuse large B-cell lymphoma, FDGPETC T radiomics predicts lung cancer gene mutations, a multicenter study on multiple myeloma PET/CT radiomics, a multicenter trial on hepatocellular carcinoma (HCC) PET/CT radiomics, and 131I combined with ATD in the treatment of patients with Graves' disease.